Skip to content
mapperlab
← Dashboard
Stock

CRVS

Corvus Pharmaceuticals, Inc.
Latest close $124 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
6
Current + past
New this quarter
1
Exited this quarter
2

Marquee-fund ownership over time

Aug 9, 2024Aug 14, 2025Feb 17, 2026May 15, 2026
Now
4

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$3.97$12+208%
Citadel Advisors re-entered$3.49$12+250%
Two Sigma Investments$3.49$12+250%
Millennium Management re-entered$3.49$12+250%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
D.E. Shaw→ $12+40%
Point72 Asset Management→ $12+253%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Corvus Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
2
Filings · last 90d
2
Total on file
219
Recent SEC buffer
Most recent
May 20, 2026

30d / 90d windows measured from May 20, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 219 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Corvus Pharmaceuticals, Inc.

Annual figures sourced directly from Corvus Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$15.28M
FY2025+75% YoY
EPS (diluted)
$-0.5300
FY2025+48% YoY
Free cash flow(?)
-$32.97M
FY2025-30% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Corvus Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Renaissance TechnologiesQ2 2026open$14$12-11%
Millennium ManagementQ1 2026open$17$12-30%
Citadel AdvisorsQ4 2025open$8.77$12+39%
D.E. ShawQ4 2025Q2 2026$8.77$12+40%
Citadel AdvisorsQ3 2024Q3 2025$3.49$4.85+39%
Two Sigma InvestmentsQ3 2024open$3.49$12+250%
Millennium ManagementQ3 2024Q3 2025$3.49$4.85+39%
Point72 Asset ManagementQ3 2024Q2 2026$3.49$12+253%
Renaissance TechnologiesQ3 2024Q4 2025$3.97$8.00+102%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.